Umecrine Cognition Secures Major Grant for Parkinson's Research
Umecrine Cognition's Breakthrough in Parkinson's Research
Karolinska Development AB, listed on Nasdaq Stockholm under the ticker KDEV, is proud to announce that its portfolio company, Umecrine Cognition, has received a significant boost in its research endeavors. Supported by a generous grant from The Michael J. Fox Foundation, totaling USD 420,000, Umecrine Cognition will advance preclinical studies on the drug candidate golexanolone, aimed at improving treatment options for Parkinson's disease.
Innovative Drug Development for Cognitive Symptoms
Umecrine Cognition is at the forefront of developing a novel class of drugs targeting cognitive symptoms associated with Parkinson's disease. Golexanolone has already shown promise in alleviating non-motor symptoms such as sleep disturbances and cognitive decline in various preclinical models. With the funding awarded by The Michael J. Fox Foundation, further studies will delve into confirming the potential advantages of golexanolone, specifically its impact on sleep dysfunction and cognitive impairments frequently observed in Parkinson's patients.
Importance of Collaborative Research
The research initiative by Umecrine Cognition is a collaboration featuring prominent neuroscientist Professor Gilberto Fisone, Head of the Laboratory of Molecular and Circuit Neuropharmacology at Karolinska Institutet. This partnership not only emphasizes the importance of academic and pharmaceutical collaboration but also highlights the potential advancements in treating Parkinson's disease, particularly regarding its often-overlooked non-motor symptoms.
Understanding Parkinson's Disease and Its Challenges
Parkinson’s disease is a progressively debilitating neurodegenerative condition primarily recognized for its impact on motor skills. Nevertheless, it is critical to understand that non-motor symptoms can manifest even before typical motor issues arise, significantly affecting patients' quality of life. Unfortunately, current therapies mainly address motor dysfunction, leaving a substantial gap in effective treatments for non-motor challenges.
“Receiving this grant from The Michael J. Fox Foundation is monumental for Umecrine Cognition and acknowledges the validity of golexanolone as a viable therapeutic option for those grappling with Parkinson's disease,” expressed Johan Dighed, General Counsel and Deputy CEO of Karolinska Development. “This funding will allow us to intensify our investigations into golexanolone, presenting a timely opportunity to explore solutions for an area long neglected in Parkinson's treatment.”
Karolinska Development holds a significant stake of 73% in Umecrine Cognition, underscoring its commitment to driving innovative healthcare solutions.
Company Contact Information
For more details, please reach out to:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
Frequently Asked Questions
What is Umecrine Cognition working on?
Umecrine Cognition is developing golexanolone, a drug aimed at alleviating cognitive symptoms associated with Parkinson's disease.
How much funding did Umecrine Cognition receive?
The company received a grant of USD 420,000 from The Michael J. Fox Foundation.
Who is collaborating with Umecrine Cognition on this research?
The principal investigator for the research collaboration is Professor Gilberto Fisone at Karolinska Institutet.
Why is this research important?
This research focuses on non-motor symptoms of Parkinson’s disease, which are often ignored by existing treatments.
What percentage of Umecrine Cognition does Karolinska Development own?
Karolinska Development holds a 73% ownership stake in Umecrine Cognition.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
